ponalrestat has been researched along with Diabetes Mellitus, Type 2 in 7 studies
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Ponalrestat administration at a dosage of 600 mg daily for 12 months has no significant effect on the course of minimal retinopathy in diabetic patients." | 2.67 | The effects of an aldose reductase inhibitor on the progression of diabetic retinopathy. ( Barendsen, BC; Hooymans, JM; Tromp, A; van Doormaal, JJ, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (28.57) | 18.7374 |
| 1990's | 5 (71.43) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boland, OM | 1 |
| Blackwell, CC | 1 |
| Clarke, BF | 1 |
| Ewing, DJ | 1 |
| Ziegler, D | 1 |
| Mayer, P | 1 |
| Rathmann, W | 1 |
| Gries, FA | 1 |
| Tromp, A | 1 |
| Hooymans, JM | 1 |
| Barendsen, BC | 1 |
| van Doormaal, JJ | 1 |
| Ramirez, LC | 1 |
| Arauz, C | 1 |
| Pruneda, L | 1 |
| Hammon, K | 1 |
| Rosenstock, J | 1 |
| Raskin, P | 1 |
| Price, DE | 2 |
| Alani, SM | 1 |
| Wales, JK | 2 |
| Airey, CM | 1 |
| Kemp, JV | 1 |
| Perkins, CM | 1 |
| Umeda, F | 1 |
| Noda, K | 1 |
| Hashimoto, T | 1 |
| Yamashita, T | 1 |
| Nawata, H | 1 |
6 trials available for ponalrestat and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Effects of ponalrestat, an aldose reductase inhibitor, on neutrophil killing of Escherichia coli and autonomic function in patients with diabetes mellitus.
Topics: Aldehyde Reductase; Analysis of Variance; Autonomic Nervous System; Blood Pressure; Diabetes Mellitu | 1993 |
One-year treatment with the aldose reductase inhibitor, ponalrestat, in diabetic neuropathy.
Topics: Aldehyde Reductase; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Dou | 1991 |
The effects of an aldose reductase inhibitor on the progression of diabetic retinopathy.
Topics: Adolescent; Adult; Aldehyde Reductase; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabeti | 1991 |
The effect of aldose reductase inhibition with ponalrestat on the width of the capillary basement membrane in diabetes mellitus.
Topics: Aldehyde Reductase; Analysis of Variance; Basement Membrane; Capillaries; Diabetes Mellitus, Type 1; | 1991 |
Effect of aldose reductase inhibition on resistance to ischemic conduction block in diabetic subjects.
Topics: Aldehyde Reductase; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Double- | 1991 |
The effect of aldose reductase inhibition on erythrocyte polyols and galactitol accumulation in diabetic patients.
Topics: Aldehyde Reductase; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, | 1989 |
1 other study available for ponalrestat and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Effect of aldose reductase inhibitor (Ponalrestat) on erythrocyte Na,K-ATPase activity in non-insulin-dependent diabetic patients with polyneuropathy.
Topics: Aldehyde Reductase; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Erythrocyte Membrane; Female; | 1989 |